A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
Sponsor: Allergan
This observational or N/A phase trial investigates Glaucoma, Primary Open Angle and Ocular Hypertension and is currently completed. Allergan leads this study, which shows 10 recorded versions since 2013 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Jan 2021 — Dec 2022 [monthly]
Completed
▶ Show 5 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed
-
Jun 2018 — May 2019 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: PHASE4 → None
-
Feb 2017 — Apr 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Allergan
For direct contact, visit the study record on ClinicalTrials.gov .